Alnylam lung drug fails mid-stage trial
Alnylam lung drug fails mid-stage trial
(Reuters) - Alnylam Pharmaceuticals Inc's experimental drug to treat a type of respiratory infection in lung transplant patients missed the main goal of a mid-stage trial. The drug, codenamed ALN-RSV01, is being developed to treat respiratory syncytial virus (RSV) infection that causes respiratory illness in young children. "We have questioned the investment in this trial since before it even began and removed all value for the RSV program from our target in January 2011," analyst Edward Tenthoff said. ...